Compare Abbott Laboratories (ABT) vs Kinder Morgan Inc (KMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Kinder Morgan Inc — how do they compare? Abbott Laboratories trades at $109.3 (market cap $187.95B), while Kinder Morgan Inc trades at $31.46 (market cap $70.10B). The key difference: Abbott Laboratories is far larger — about 2.7× Kinder Morgan Inc's market cap, and Kinder Morgan Inc pays the higher dividend (3.75%). Which is the better fit depends on your goals.
| ABT | KMI | |
|---|---|---|
Market Cap | $187.95B | $70.10B |
Sector | Health | Energy |
52-Week High | $136.62 | $34.31 |
52-Week Low | $82.57 | $25.84 |
Enterprise Value | $214.96B | $102.15B |
Dividend Yield | 2.32% | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
KMI trades at $31.39, up 1.75% today, with a bearish technical signal but strong fundamentals including consistent earnings beats and a 19.31% net income margin. Recent news highlights a $5 billion Western Gateway Pipeline joint venture with Phillips 66 and HF Sinclair, signaling growth in energy infrastructure.
The outlook is mixed: robust cash flow and dividend sustainability support income investors, but high debt levels and bearish technical indicators pose risks. Analyst consensus is nearly split between Buy and Hold, reflecting cautious optimism amid valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →
